These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 31878857)
1. Integrated Protocol to Design Potential Inhibitors of Dipeptidyl Peptidase- 4 (DPP-4). Pantaleão SQ; Philot EA; de Oliveira Almeida M; Lima AN; de Sairre MI; Scott AL; Honorio KM Curr Top Med Chem; 2020; 20(3):209-226. PubMed ID: 31878857 [TBL] [Abstract][Full Text] [Related]
2. Martins MCMR; Pantaleao SQ; de Oliveira Almeida M; Weber KC; Honorio KM Med Chem; 2021; 17(3):247-263. PubMed ID: 31995015 [TBL] [Abstract][Full Text] [Related]
3. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors. Li N; Wang LJ; Jiang B; Guo SJ; Li XQ; Chen XC; Luo J; Li C; Wang Y; Shi DY Bioorg Med Chem Lett; 2018 Jul; 28(12):2131-2135. PubMed ID: 29773502 [TBL] [Abstract][Full Text] [Related]
6. DPP-IV Inhibitory Phenanthridines: Ligand, Structure-Based Design and Synthesis. Khalaf RA; Masalha D; Sabbah D Curr Comput Aided Drug Des; 2020; 16(3):295-307. PubMed ID: 30526469 [TBL] [Abstract][Full Text] [Related]
7. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation. Meduru H; Wang YT; Tsai JJ; Chen YC Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Musoev A; Numonov S; You Z; Gao H Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors. Li Q; Zhou M; Han L; Cao Q; Wang X; Zhao L; Zhou J; Zhang H Chem Biol Drug Des; 2015 Oct; 86(4):849-56. PubMed ID: 25787859 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors. Li Q; Han L; Zhang B; Zhou J; Zhang H Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, Structural Characterization and Docking Studies of Sulfamoyl- Phenyl Acid Esters as Dipeptidyl Peptidase-IV Inhibitors. Khalaf RA; Sabbah D; Al-Shalabi E; Al-Sheikh I; Albadawi G; Abu Sheikha G Curr Comput Aided Drug Des; 2018; 14(2):142-151. PubMed ID: 29521244 [TBL] [Abstract][Full Text] [Related]
13. A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. Kumar S; Mittal A; Mittal A Bioorg Med Chem; 2021 Sep; 46():116354. PubMed ID: 34428715 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM). Shao DW; Zhao LJ; Sun JF Eur J Med Chem; 2024 Jun; 272():116464. PubMed ID: 38704940 [TBL] [Abstract][Full Text] [Related]
15. Structure-based virtual screening of dipeptidyl peptidase 4 inhibitors and their in vitro analysis. Rahman SU; Ali HS; Jafari B; Zaib S; Hameed A; Al-Kahraman YMSA; Langer P; Iqbal J Comput Biol Chem; 2021 Apr; 91():107326. PubMed ID: 32739275 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes. Kushwaha RN; Srivastava R; Mishra A; Rawat AK; Srivastava AK; Haq W; Katti SB Chem Biol Drug Des; 2015 Apr; 85(4):439-46. PubMed ID: 25216392 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors. Liu Y; Wu Y; Wu H; Tang L; Wu P; Liu T; Hu Y Chem Biol Drug Des; 2013 Aug; 82(2):140-6. PubMed ID: 23530834 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors. Zhang L; Su M; Li J; Ji X; Wang J; Li Z; Li J; Liu H Chem Biol Drug Des; 2013 Feb; 81(2):198-207. PubMed ID: 22994702 [TBL] [Abstract][Full Text] [Related]
19. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides. Sivaraman SA; Sabareesh V Curr Protein Pept Sci; 2024; 25(4):267-285. PubMed ID: 38173201 [TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses. Mohanty IR; Borde M; Kumar C S; Maheshwari U Phytomedicine; 2019 Apr; 57():158-165. PubMed ID: 30668318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]